CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Authors

Bicky Thapa, Medical College of Wisconsin
Paolo F. Caimi, Case Western Reserve University
Kirit M. Ardeshna, University College London Hospitals
Melhem Solh, Northside Hospital, Atlanta, GA
Carmelo Carlo-Stella, Humanitas University
Brad S. Kahl, Washington University School of Medicine in St. Louis
Mehdi Hamadani, Medical College of Wisconsin

Journal

Blood Advances

Publication Date

2020

Volume

4

Issue

16

First Page

3850

Last Page

3852

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2020002587

Rights and Permissions

Bicky Thapa, Paolo F. Caimi, Kirit M. Ardeshna, Melhem Solh, Carmelo Carlo-Stella, Brad S. Kahl, Mehdi Hamadani; CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv 2020; 4 (16): 3850–3852. doi: https://doi.org/10.1182/bloodadvances.2020002587

Recommended Citation

Thapa, Bicky; Caimi, Paolo F.; Ardeshna, Kirit M.; Solh, Melhem; Carlo-Stella, Carmelo; Kahl, Brad S.; and Hamadani, Mehdi, "CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy." Blood Advances. 4, 16. 3850 - 3852. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9817